Cytomegalovirus (CMV)-specific cytotoxic T lymphocyte therapy resolve CMV diseases and refractory CMV infections in paediatric recipients of allogeneic haematopoietic stem cell transplantation.
作者信息
Wang Xiaodong, Yu Uet, Yang Chunlan, Wang Chunjing, Zhang Xiaoling, Li Yue, Li Changgang, Wen Feiqiu, Liu Sixi
机构信息
Department of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen, China.
出版信息
Bone Marrow Transplant. 2022 Feb;57(2):271-275. doi: 10.1038/s41409-021-01499-0. Epub 2021 Oct 20.
Abstract
摘要
相似文献
1
Cytomegalovirus (CMV)-specific cytotoxic T lymphocyte therapy resolve CMV diseases and refractory CMV infections in paediatric recipients of allogeneic haematopoietic stem cell transplantation.
Bone Marrow Transplant. 2022 Feb;57(2):271-275. doi: 10.1038/s41409-021-01499-0. Epub 2021 Oct 20.
2
Donor CMV-specific cytotoxic T lymphocytes successfully treated drug-resistant cytomegalovirus encephalitis after allogeneic hematopoietic stem cell transplantation.
Hematology. 2020 Dec;25(1):43-47. doi: 10.1080/16078454.2019.1710945.
3
[Cytomegalovirus specific cytotoxic T lymphocytes for treatment of refractory cytomegalovirus infection in patients following allogeneic hematopoietic stem cell transplantation].
Zhonghua Nei Ke Za Zhi. 2015 Feb;54(2):101-5.
4
Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation.
Blood. 2001 Mar 1;97(5):1232-40. doi: 10.1182/blood.v97.5.1232.
5
Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity.
Blood. 2003 Jan 15;101(2):407-14. doi: 10.1182/blood-2002-03-0993. Epub 2002 Sep 12.
6
Cytomegalovirus-specific cytotoxic T lymphocytes can be efficiently expanded from granulocyte colony-stimulating factor-mobilized hemopoietic progenitor cell products ex vivo and safely transferred to stem cell transplantation recipients to facilitate immune reconstitution.
Biol Blood Marrow Transplant. 2013 May;19(5):725-34. doi: 10.1016/j.bbmt.2013.01.021. Epub 2013 Feb 1.
7
Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation.
Biol Blood Marrow Transplant. 2007 Jun;13(6):707-14. doi: 10.1016/j.bbmt.2007.02.004. Epub 2007 Apr 6.
8
T-cell receptor repertoire of cytomegalovirus-specific cytotoxic T-cells after allogeneic stem cell transplantation.
Sci Rep. 2020 Dec 17;10(1):22218. doi: 10.1038/s41598-020-79363-2.
9
Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and non-relapse mortality.
Clin Microbiol Infect. 2015 Dec;21(12):1121.e9-15. doi: 10.1016/j.cmi.2015.06.009. Epub 2015 Jun 17.
10
Resistant or refractory cytomegalovirus infections after hematopoietic cell transplantation: diagnosis and management.
Curr Opin Infect Dis. 2019 Dec;32(6):565-574. doi: 10.1097/QCO.0000000000000607.
引用本文的文献
1
[Chinese expert consensus on the diagnosis and treatment strategies for refractory/resistant cytomegalovirus infection in immunocompromised populations (2025)].
Zhonghua Xue Ye Xue Za Zhi. 2025 May 14;46(5):402-409. doi: 10.3760/cma.j.cn121090-20250112-00024.
2
Investigation of the infection route of HIV-associated cytomegalovirus retinitis.
Int J Ophthalmol. 2025 Mar 18;18(3):478-486. doi: 10.18240/ijo.2025.03.15. eCollection 2025.
3
Dynamic findings of brain magnetic resonance imaging in a haploidentical hematopoietic stem cell transplantation recipient with cytomegalovirus ventriculoencephalitis: a case report and systematic review.
Front Immunol. 2024 Sep 20;15:1450576. doi: 10.3389/fimmu.2024.1450576. eCollection 2024.
4
Cytomegalovirus Retinitis: Clinical Manifestations, Diagnosis and Treatment.
Viruses. 2024 Sep 7;16(9):1427. doi: 10.3390/v16091427.
5
Clinical manifestations, prognostic factors, and outcomes of adenovirus pneumonia after allogeneic hematopoietic stem cell transplantation.
Virol J. 2024 May 14;21(1):110. doi: 10.1186/s12985-024-02383-1.
6
Mucosal T-cell responses to chronic viral infections: Implications for vaccine design.
Cell Mol Immunol. 2024 Sep;21(9):982-998. doi: 10.1038/s41423-024-01140-2. Epub 2024 Mar 8.
7
Refractory cytomegalovirus infections in Chinese patients receiving allogeneic hematopoietic cell transplantation: a review of the literature.
Front Immunol. 2023 Dec 22;14:1287456. doi: 10.3389/fimmu.2023.1287456. eCollection 2023.
8
Virus-Specific T-Cell Therapy for Viral Infections of the Central Nervous System: A Review.
Viruses. 2023 Jul 6;15(7):1510. doi: 10.3390/v15071510.
9
Prevention and management of human cytomegalovirus in pediatric HSCT recipients: A review.
Front Pediatr. 2022 Nov 23;10:1039938. doi: 10.3389/fped.2022.1039938. eCollection 2022.
10
Adoptive Immunotherapy for Prophylaxis and Treatment of Cytomegalovirus Infection.
Viruses. 2022 Oct 27;14(11):2370. doi: 10.3390/v14112370.
本文引用的文献
1
The CD4+ T Cell Response to Human Cytomegalovirus in Healthy and Immunocompromised People.
Front Cell Infect Microbiol. 2020 May 19;10:202. doi: 10.3389/fcimb.2020.00202. eCollection 2020.
2
Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7).
Lancet Infect Dis. 2019 Aug;19(8):e260-e272. doi: 10.1016/S1473-3099(19)30107-0. Epub 2019 May 29.
3
First-line Therapy With Donor-derived Human Cytomegalovirus (HCMV)-specific T Cells Reduces Persistent HCMV Infection by Promoting Antiviral Immunity After Allogenic Stem Cell Transplantation.
Clin Infect Dis. 2020 Mar 17;70(7):1429-1437. doi: 10.1093/cid/ciz368.
4
Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus.
Cytotherapy. 2015 Aug;17(8):1139-51. doi: 10.1016/j.jcyt.2015.04.011. Epub 2015 Jun 10.
5
Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation.
Blood. 2013 May 2;121(18):3745-58. doi: 10.1182/blood-2012-08-448977. Epub 2013 Feb 22.
6
Immunological monitoring for guidance of preemptive antiviral therapy for active cytomegalovirus infection in allogeneic stem-cell transplant recipients: a pilot experience.
Transplantation. 2011 Aug 27;92(4):e17-20. doi: 10.1097/TP.0b013e318224f263.
7
Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation.
Blood. 2010 Nov 18;116(20):4360-7. doi: 10.1182/blood-2010-01-262089. Epub 2010 Jul 12.
8
Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation.
Clin Infect Dis. 2009 Dec 15;49(12):1851-60. doi: 10.1086/648422.
9
Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation.
Blood. 2001 Mar 1;97(5):1232-40. doi: 10.1182/blood.v97.5.1232.
Zotero 插件